Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,126 | 164 | 934 |
| Samples | 539 | 95 | 427 |
| Peptides | 403 | 71 | 339 |
Function
MAN2B1 · Mannosidase alpha class 2B member 1
This gene encodes an enzyme that hydrolyzes terminal, non-reducing alpha-D-mannose residues in alpha-D-mannosides. Its activity is necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover and it is member of family 38 of glycosyl hydrolases. The full length protein is processed in two steps. First, a 49 aa leader sequence is cleaved off and the remainder of the protein is processed into 3 peptides of 70 kDa, 42 kDa (D) and 13/15 kDa (E). Next, the 70 kDa peptide is further processed into three peptides (A, B and C). The A, B and C peptides are disulfide-linked. Defects in this gene have been associated with lysosomal alpha-mannosidosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2010].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 391 amino-acid changes on canonical ENST00000456935 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MAN2B1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MAN2B1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 10/40 25% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 35/612 6% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Acute Monocytic Leukemia | 1/1 100% | 0/25 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Colorectal Carcinoma | 23/143 16% | 76/3239 2% |
| Cervical Carcinoma | 0/35 0% | 13/422 3% |
| Melanoma | 6/210 3% | 48/1899 3% |
| Other Solid Cancers | 0/94 0% | 35/1515 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Gastric Carcinoma | 2/74 3% | 35/1809 2% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 13/1390 1% |
| Bladder Carcinoma | 2/58 3% | 14/956 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 17/1592 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Neuroendocrine Tumour | 3/154 2% | 4/577 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 7/810 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Other Sarcomas | 1/69 1% | 6/699 1% |
| Plasma Cell Myeloma | 1/44 2% | 2/305 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Ovarian Carcinoma | 2/109 2% | 6/998 1% |
| Glioma | 0/52 0% | 15/2127 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 18/2550 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Biliary Tract Carcinoma | 1/54 2% | 5/950 1% |
| Hepatocellular Carcinoma | 0/46 0% | 13/2210 1% |
Mutation Distribution
Where MAN2B1 is mutated · all tissues, split by cell line vs tissue
How many mutations in MAN2B1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,126 mutations in MAN2B1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|